Alamar Biosciences, Inc. (NASDAQ:ALMR) Given Average Recommendation of “Moderate Buy” by Analysts

Posted by Casey Walker on Jul 26th, 2026

Shares of Alamar Biosciences, Inc. (NASDAQ:ALMR – Get Free Report) have received an average rating of “Moderate Buy” from the six analysts that are currently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $30.00.

A number of brokerages recently issued reports on ALMR. Stifel Nicolaus began coverage on shares of Alamar Biosciences in a research note on Tuesday, May 12th. They issued a “buy” rating and a $28.00 price target for the company. Zacks Research raised shares of Alamar Biosciences to a “hold” rating in a report on Wednesday, May 13th. TD Cowen reissued a “buy” rating on shares of Alamar Biosciences in a research report on Wednesday, July 15th. Leerink Partners initiated coverage on shares of Alamar Biosciences in a research note on Tuesday, May 12th. They issued an “outperform” rating and a $35.00 target price on the stock. Finally, Wall Street Zen raised shares of Alamar Biosciences to a “hold” rating in a research report on Saturday, April 25th.

Check Out Our Latest Stock Analysis on Alamar Biosciences

Alamar Biosciences Trading Down 0.0%

Shares of NASDAQ ALMR opened at $25.88 on Friday. Alamar Biosciences has a fifty-two week low of $18.84 and a fifty-two week high of $29.43. The company’s 50 day simple moving average is $23.21. The firm has a market cap of $1.79 billion and a price-to-earnings ratio of -14.87.

Alamar Biosciences (NASDAQ:ALMR – Get Free Report) last announced its earnings results on Friday, May 8th. The company reported ($1.74) earnings per share (EPS) for the quarter. The business had revenue of $26.04 million during the quarter.

Alamar Biosciences Company Profile

(Get Free Report)

Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation.